GS-1811 is currently in the Phase I clinical development as a possible treatment for solid tumours patients. Credit: Atlas of Pulmonary Pathology / Flickr (Creative Commons).

Gilead Sciences and Jounce Therapeutics have amended their current license agreement for first-in-class immunotherapy, GS-1811 (formerly JTX-1811).

The initial license agreement was signed in 2020.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The amended agreement will allow Gilead Sciences to acquire all the remaining rights for GS-1811 from Jounce Therapeutics.

Certain operational obligations of the companies that are related to GS-1811 have also been terminated as part of the transaction.

Pursuant to the deal, Gilead will also buy certain related intellectual property along with all the outstanding rights to GS-1811 from Jounce.

Now, the company will be solely responsible for all further research, development, and commercialisation of GS-1811 across the world.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

For the deal, Jounce will receive $67m from Gilead and is no longer entitled to receive the remaining contingent payments of up to $645m in milestones and royalties under the original agreement.

Gilead Oncology Therapeutic Area head senior vice president Bill Grossman said: “Today’s news about GS-1811 further demonstrates our commitment to our rapidly evolving oncology franchise and mission of pioneering next-generation medicines for people with cancer.

“GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with a treatment that works from inside cancerous cells to shrink solid tumours.”

The anti-CCR8 antibody, GS-1811 has been designed to reduce immunosuppressive tumour-infiltrating T regulatory cells selectively in the tumour microenvironment.

It is currently being evaluated in Phase I clinical trial for the treatment of solid tumours.

Jounce CEO and president Richard Murray said: “This transaction allows us to extend our runway and remain focused on delivering meaningful and long-lasting benefits to cancer patients.”

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now